Aktienanalyse zu Imunon Inc (IMNN)IMNNImunon Inc

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Imunon Inc (IMNN) is currently not a good buy due to its low price of $0.85, which is significantly down 78.45% year-to-date, and an RSI of 31.317 indicating oversold conditions. The company is facing substantial financial losses, with a net income loss of $2.8 million in Q2 2026 and a forward P/E ratio of 16.7785 suggesting potential overvaluation despite the recent positive trial results. The main risk is the upcoming earnings report on November 12, 2026, where an EPS estimate of -0.6100 could further impact the stock negatively if not met.